Bioceres' Q4 2024 Shows Challenges With HB4 Rollout, Still A Hold Despite Lower Stock Prices
Bioceres' 4Q24 results disappointed, with flat profitability and a 15% stock drop, driven by a bear market in agricultural commodities and commercialization challenges for HB4 products. The company's debt rose, particularly short term, with unclear maturity risks, and profitability challenges persisted despite top-line growth. Bioceres is shifting tactics for HB4, reducing the priority of its identity-protected program to manage working capital and focusing more on its bio solutions segment.
Bioceres Crop Solutions Corp. (BIOX) Q4 2024 Earnings Call Transcript
Bioceres Crop Solutions Corp. (NASDAQ:BIOX ) Q4 2024 Earnings Conference Call September 10, 2024 8:30 AM ET Company Participants Paula Savanti - Head of IR Federico Trucco - CEO Enrique Lopez Lecube - CFO Conference Call Participants Ben Klieve - Lake Street Capital Markets Kristen Owen - Oppenheimer Kemp Dolliver - Brookline Capital Markets Austin Moeller - Canaccord Scott Fortune - ROTH Capital Partners Operator Good morning. Welcome to today's Bioceres Crop Solutions, Fiscal Fourth Quarter and Full Year 2024 Financial Results Conference call.
